Trial Profile
Evaluation of the Safety and Efficacy of Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment of Malaria in HIV-infected Pregnant Women
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Dihydroartemisinin/piperaquine (Primary)
- Indications Malaria
- Focus Therapeutic Use
- Acronyms MAMAH
- 18 Jul 2023 Status changed from active, no longer recruiting to completed.
- 27 Feb 2023 Planned End Date changed from 1 Nov 2022 to 1 Jul 2023.
- 27 Feb 2023 Planned primary completion date changed from 1 Nov 2021 to 1 Jul 2023.